Cargando…

Egyptian practical guidance in lipid management 2020

BACKGROUND: Numerous epidemiological investigations and randomized clinical studies have determined that dyslipidemia is a major contributor to atherosclerotic cardiovascular disease (ASCVD). Consequently, the management of serum cholesterol and low-density lipoprotein levels has become a central ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Taha, Hesham Salah El Din, Badran, Hala Mahfouz, Kandil, Hossam, Farag, Nabil, Oraby, Abbas, El Sharkawy, Magdy, Shokry, Khaled, Fawzy, Fouad, Mahrous, Hossam, Bahgat, Juliette, Samy, Mina, Shaker, Mirna Mamdouh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902744/
https://www.ncbi.nlm.nih.gov/pubmed/33620601
http://dx.doi.org/10.1186/s43044-021-00140-1
Descripción
Sumario:BACKGROUND: Numerous epidemiological investigations and randomized clinical studies have determined that dyslipidemia is a major contributor to atherosclerotic cardiovascular disease (ASCVD). Consequently, the management of serum cholesterol and low-density lipoprotein levels has become a central objective in the effort to prevent cardiovascular events. MAIN BODY: Many guidelines were issued by different organizations and societies to define patient risk and establish important recommendations for management strategies. Newer cholesterol-lowering agents (non-statin drugs) are described, and their use is directed primarily to secondary prevention in patients at very high risk of new ASCVD. CONCLUSION: The present guidance summarizes the current methods for risk estimation and outlines the most recent data on lipid management in a simple user-friendly format, to improve physician awareness and help implement guidelines in the daily practice.